Pathologic myopia is a leading cause of visual impairment. Development of myopic choroidal neovascularization (CNV) is one of the most common complications that leads to central vision loss in patients with pathologic myopia. If left untreated, it can cause scarring with expanding macular atrophy leading to irreversible visual loss in a period as short as 5 years. Advancements in multimodal imaging technology have furthered our understanding of the condition; however, further studies are necessary to extend its utility in the diagnosis of myopic CNV. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy has become the standard-of-care and the recommended first-line treatment option for myopic CNV. Long-term studies have demonstrated that early treatment of confirmed myopic CNV cases with an intravitreal anti-VEGF agent is useful to avoid late-stage complications. This strategy has also been shown to achieve visual outcome improvements for up to 4 years and visual stabilization up to 6 years. This review article provides an overview of the current knowledge on myopic CNV and discusses recent updates in the diagnosis and management of the condition. Furthermore, treatment recommendations are provided based on the authors’ expert opinions.

病理性近视是视力障碍的主要原因。近视脉络膜新生血管的形成（CNV）是导致病理性近视患者中心视力丧失的最常见并发症之一。如果不加以治疗，可能会在短短5年的时间内使瘢痕形成的黄斑萎缩扩大，导致不可逆的视力丧失。多峰成像技术的进步进一步加深了我们对病情的认识。但是，有必要进行进一步的研究以扩展其在近视CNV诊断中的应用。玻璃体内抗血管内皮生长因子（anti-VEGF）治疗已成为近视CNV的治疗标准和推荐的一线治疗选择。长期研究表明，使用玻璃体内抗VEGF药物早期治疗确诊的近视CNV病例有助于避免后期并发症。该策略还被证明可以达到长达4年的视觉效果改善和长达6年的视觉稳定。这篇综述文章概述了有关近视CNV的最新知识，并讨论了该病的诊断和治疗方面的最新进展。此外，根据作者的专家意见提供了治疗建议。这篇综述文章概述了有关近视CNV的最新知识，并讨论了该病的诊断和治疗方面的最新进展。此外，根据作者的专家意见提供了治疗建议。这篇综述文章概述了有关近视CNV的最新知识，并讨论了该病的诊断和治疗方面的最新进展。此外，根据作者的专家意见提供了治疗建议。